Ernexa Therapeutics Inc. harnesses its proprietary synthetic induced pluripotent stem cell-derived mesenchymal stem cell (iMSC) platform to develop off-the-shelf treatments targeting cancer and autoimmune disorders. Despite operating preclinically with no revenue growth over recent years, the company has narrowed operating losses and improved cash flow metrics, supported by multiple equity financings including a $10.5 million raise in early 2026. Crucial near-term catalysts center on FDA interactions, Phase 1 trial readiness, and navigating manufacturing complexities under cGMP standards. Risks persist around regulatory approval, manufacturing scale-up, and intellectual property protection amid a competitive cell therapy landscape.